ANPCF News and Press, Angle Plc Ord From 04/08/24

PARSORTIX HER2 ASSAY SHOWCASED AT PRESTIGIOUS INTERNATIONAL CANCER CONFERENCE CTC HER2 assay being developed for HER2 targeted drugs and antibody drug conjugates presented at internationally renowned AACR Annual Meeting 2024 GUILDFORD, SURREY / ACCESSWIRE / April 8, 2024 / ANG...

PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT A LEADING EUROPEAN BREAST CANCER CONFERENCE ANGLE presenting two posters highlighting the utility of the Company's new Portrait+ CTC Staining Kit and Portrait HER2 assay GUILDFORD, SURREY / ACCESSWIRE / March 22, 2024 / ANGLE plc (AIM:AG)(O...

REVIEW PAPER ON MOLECULAR ANALYSIS OF PARSORTIX CTC HARVEST HIGHLIGHTS POTENTIAL UTILITY IN PRECISION ONCOLOGY Paper published in the journal "Current Issues in Molecular Biology" special issue: advanced solutions for cancer therapy GUILDFORD, SURREY / ACCESSWIRE / January 22, 2024 / AN...

USE OF PARSORTIX SYSTEM IN PRE-CLINICAL MODEL UNLOCKS OPPORTUNITIES FOR DRUG DISCOVERY Harvested CTCs reveal gene expression profile associated with development and progression of brain metastasis in melanoma Researchers suggest such profiling could prove to be "pivotal" to prescribing m...

GUILDFORD, SURREY / ACCESSWIRE / December 11, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, is pleased to announce that Berenberg will ...

ANGLE LAUNCHES PD-L1 TEST TO SUPPORT CANCER THERAPY STUDIES ANGLE's Portrait PD-L1 test uses CTCs harvested from the Parsortix system to investigate real-time patient PD-L1 status for clinical studies The test is designed for highly accurate, repeatable, and precise results for CTC PD-L...

RESEARCH DEMONSTRATES POTENTIAL OF THE PARSORTIX SYSTEM TO SUPPORT POWERFUL CHARACTERISATION OF CTCS IN HEAD AND NECK CANCER 41 key biomarkers including the immune checkpoint proteins PD-L1, CTLA4 and CD39 successfully evaluated Providing key information which could support the developm...

Interim Results for the six months ended 30 June 2023 BUILDING COMMERCIAL MOMENTUM DELIVERS REVENUE GROWTH Cash runway extended into Q1 2025 GUILDFORD, SURREY / ACCESSWIRE / September 7, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative ...

GUILDFORD, SURREY / ACCESSWIRE / June 28, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed. For further information: Notes for editors About ANG...

Brett Swansiger joins as Chief Commercial Officer Karen Miller PhD joins as Chief Scientific Officer GUILDFORD, SURREY / ACCESSWIRE / June 5, 2023 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce the appointments of Br...